Morgan Stanley Holds $42 Chewy Target After 11% Stock Drop
Morgan Stanley keeps its Overweight rating on Chewy despite an 11% selloff, seeing over 120% upside tied to vet clinics and customer growth.
Morgan Stanley is standing firm on its bullish thesis for Chewy even as the pet-products retailer's stock tumbled more than 11% following a trimmed revenue guidance update. The investment bank maintained its "Overweight" rating and kept its price target at $42 — a figure that implies upside exceeding 120% from current trading levels. That kind of gap between a Wall Street target and market price is uncommon, and it signals that the firm views the selloff as an overreaction rather than a fundamental deterioration.
At the heart of Morgan Stanley's conviction is a belief that Chewy's stock price has become untethered from the company's underlying business reality. The analysts point to continued profitability, resilient customer dynamics, and what they see as a meaningful long-term growth catalyst: the expansion of Chewy's veterinary clinic network. Vet services represent a higher-margin, stickier revenue stream than e-commerce retail alone, and the firm appears to be pricing in a future where that segment gains meaningful traction.
Read more Church & Dwight Stock Sits Quiet With No Fresh Catalysts →
The $42 target, however, comes with explicit conditions. Morgan Stanley frames it as a long-term call that depends on Chewy continuing to add customers, demonstrating that its vet clinic rollout is gaining commercial momentum, and benefiting from a more stable macroeconomic backdrop. That last condition is notable — it acknowledges that consumer spending pressures and broader economic uncertainty are real headwinds that could delay rather than derail the thesis.
For investors trying to interpret the signal here, the key tension is between near-term guidance cuts and longer-term structural positioning. Chewy's reduced revenue outlook spooked the market, but Morgan Stanley's analysts are essentially arguing that the market is discounting a durable business at distressed-asset prices. Whether that view proves prescient depends heavily on how quickly the vet clinic expansion translates into revenue and how long macro softness weighs on discretionary pet spending.
Continue reading at Yahoo Finance Singapore.
